.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,550,433

« Back to Dashboard

Claims for Patent: 7,550,433

Title:Erythropoietin receptor peptide formulations and uses
Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, and dosages are also provided.
Inventor(s): Duliege; Anne-Marie (Palo Alto, CA), Stead; Richard (Bellevue, WA), Leuther; Kerstin (San Jose, CA), Woodburn; Kathryn (Saratoga, CA), Naso; Robert Barnett (Menlo Park, CA)
Assignee: Affymax, Inc. (Palo Alto, CA)
Application Number:11/446,593
Patent Claims: 1. A method for treating a patient having a disorder characterized by a deficiency of erythropoietin or a low or defective red blood cell population, which method comprises administering once every 3 to 4 weeks to the patient a therapeutically effective amount of a compound that binds to and activates the erythropoietin receptor (EPO-R), wherein the therapeutically effective amount is a dosage of 0.025 to 0.5 milligram of the compound per 1 kilogram of body weight of the patient, wherein the compound comprises: (a) a first peptide monomer and a second peptide monomer, each of said first and second peptide monomers comprising the amino acid sequence (AcG)GLYACHMGPIT(1-nal)VCQPLR (SEQ ID NO: 14); (b) a linker moiety covalently bonding the first peptide monomer to the second peptide monomer; and (c) a spacer moiety covalently joining the linker moiety and a poly(ethylene glycol) (PEG) moiety, said PEG moiety comprising a linear, unbranched PEG having molecular weight of 10,000 to 60,000 Daltons.

2. The method of claim 1, wherein the amino acid sequence additionally comprises (MeG), K, or (MeG)K.

3. The method of claim 2, wherein the amino acid sequence is (AcG)GLYACHMGPIT(1-nal)VCQPLRK (SEQ ID NO: 1).

4. The method of claim 2, wherein the amino acid sequence is (AcG)GLYACHMGPIT(1-nal)VCQPLR(MeG) (SEQ ID NO: 3).

5. The method of claim 2, wherein the amino acid sequence is (AcG)GLYACHMGPIT(1-nal)VCQPLR(MeG)K (SEQ ID NO: 2).

6. The method of claim 1, wherein the spacer moiety is an iminodiacetic moiety.

7. The method of claim 1, wherein the spacer moiety has the formula: ##STR00121## wherein R.sub.4 is selected from the group consisting of NH, NHCO, CO, COO, and NHCOO.

8. The method of claim 1, wherein the linker moiety is lysine.

9. The method of claim 1, wherein the PEG moiety has a molecular weight of 10,000 to 50,000 Daltons.

10. The method of claim 9, wherein the PEG moiety has a molecular weight of 20,000 to 40,000 Daltons.

11. The method of claim 1, wherein the compound is administered with a pharmaceutically acceptable carrier.

12. The method of claim 1, wherein the disorder is renal failure or dialysis.

13. The method of claim 12, wherein the therapeutically effective amount is a dosage of 0.025 to 0.2 milligram of the compound per 1 kilogram of body weight of the patient.

14. The method of claim 13, wherein the dosage is 0.05 to 0.1 milligram of the compound per 1 kilogram of body weight of the patient.

15. The method of claim 1, wherein the disorder is anemia associated with a malignancy.

16. The method of claim 15, wherein the therapeutically effective amount is a dosage of 0.075 to 0.5 milligram of the compound per 1 kilogram of body weight of the patient

17. The method of claim 16, wherein the dosage is 0.2 to 0.4 milligram of the compound per 1 kilogram of body weight of the patient.

18. A method for treating a patient having a disorder characterized by a deficiency of erythropoietin or a low or defective red blood cell population, which method comprises administering once every 3 to 4 weeks to the patient a therapeutically effective amount of a compound that binds to and activates the erythropoietin receptor (EPO-R), wherein the therapeutically effective amount is a dosage of 0.025 to 0.5 milligram of the compound per 1 kilogram of body weight of the patient, wherein the compound is: ##STR00122##

19. The method of claim 1 or 18, wherein the therapeutically effective amount is administered once every 3 weeks.

20. The method of claim 1 or 18, wherein the therapeutically effective amount is administered once every 4 weeks.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc